

Bibliography Wolfgang Köhler (March 2018)

Original articles and reviews

1. Fischer M, **Köhler W**, Faiss JH, Hoffmann F, Kunkel A, Sailer M, Schwab M, Zettl UK, Bublak P on behalf of the HIPPOCOMS Study Group. A smart peek: visual attention capacity in early versus late multiple sclerosis and its relation to cognitive ability. *Europ J Neurol* 2018 (submitted).
2. Nils Waldhüter, **Wolfgang Köhler**, Philipp G. Hemmati, Christian Jehn, Rudolf Peceny, Giang L. Vuong, Renate Arnold, Jörn-Sven Kühl. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for adult cerebral X-linked adrenoleukodystrophy. *Journal of Inherited Metabolic Disease* 2018 (in press).
3. Jörn-Sven Kühl, Jana Kupper, Hermann Baqué, Wolfram Ebell, Jutta Gärtner, Christoph Korenke, Birgit Spors, Ingo G. Steffen, Gabriele Strauss, Sebastian Voigt, Bernhard Weschke, Almuth Weddige, **Wolfgang Köhler**, Robert Steinfeld. Potential risk pattern factors for stable long-term outcome after allogeneic hematopoietic stem cell transplantation for childhood cerebral X-linked adrenoleukodystrophy. *JAMA Network Open*:(3)1,2018 .e180769.doi:10.1001/jamanetworkopen.2018.0769
4. Weinhofer, Isabelle, Zierfuss, Bettina; Hametner, Simon;Wagner, Magdalena; Popitsch, Niko; Machacek, Christian; Bartolini, Barbara; Zlabinger, Gerhard; Ohradanova-Repic, Anna; Stockinger, Hannes; **Köhler, Wolfgang**; Höftberger, Romana; Regelsberger, Günther; Forss-Petter, Sonja; Lassmann, Hans; Berger, Johannes. Impaired plasticity of macrophages in X-linked adrenoleukodystrophy. *Brain*. 2018 May 30. doi: 10.1093/brain/awy127
5. Hoffmann F, Kraft A, Heigl F, Mauch E, Koehler J. Harms L, Kümpfel T, **Köhler W**, Ehrlich S, Bayas Antonios, Weinmann-Menke J, Beuker C, Henn KH, Ayzenberg I, Ellrichmann G, Hellwig K, Klingel R, Fassbender CM, Fritz H, Slowinski T, Weihprecht H, Brand M, Stiegler T, Galle J, Schimrigk S. Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. *Ther Adv Neurol Disord*, 2018 11:1-12.
6. Hamilton EMC, Tekturk P, Cialdella F, van Rappard DF, Wolf NI, Yalcinkaya C, Çetinçelik Ü, Rajae A, Kariminejad A, Paprocka J, Yapici Z, Bošnjak VM, van der Knaap MS; **MLC Research Group**. Megalencephalic leukoencephalopathy with subcortical cysts: Characterization of disease variants. *Neurology*. 2018 Apr 17;90(16):e1395-e1403.
7. Mendes MI, Gutierrez Salazar M, Guerrero K, Thiffault I, Salomons GS, Gauquelin L, Tran LT, Forget D, Gauthier MS, Waisfisz Q, Smith DEC, Simons C, van der Knaap MS, Marquardt I, Lemes A, Mierzewska H, Weschke B, **Koehler W**, Coulombe B, Wolf NI, Bernard G. Bi-allelic Mutations in EPRS, Encoding the Glutamyl-Prolyl-Aminoacyl-tRNA Synthetase, Cause a Hypomyelinating Leukodystrophy. *Am J Hum Genet*. 2018 Apr 5;102(4):676-684.
8. **Köhler W**, Curiel J, Vanderver A. Adulthood leukodystrophies. *Nat Rev Neurol*. 2018 Feb;14(2):94-105.
9. **Köhler W**, Fischer M, Bublak P, Faiss JH, Hoffmann F, Kunkel A, Sailer M, Schwab M, Stadler E, Zettl UK, Penner IK; HIPPOCOMS Study Group. Information processing deficits as a driving force for memory impairment in MS: A cross-sectional study of memory functions and MRI in early and late stage MS. *Mult Scler Relat Disord*. 2017 Nov;18:119-127.

10. Fassbender C, Klingel R, **Köhler W**. Immunoabsorption for autoimmune encephalitis. *Atheroscler Suppl.* 2017 Nov;30:257-263.
11. Jörn-Sven Kühl, Felipe Suarez, Godfrey Gillett, Philipp Hemmati, John Snowden, Michael Stadler, Giang L. Vuong, Patrick Aubourg, **Wolfgang Köhler**, Renate Arnold. Long-term outcomes after allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy. *Brain* (2017) 140:753-766.
12. Antonella Castellano, Nico Papinutto, Marcello Cadioli, Gianluca Brugnara, Antonella Iadanza, Graziana Scigliuolo, Davide Pareyson, Graziella Uziel, **Wolfgang Köhler**, Patrick Aubourg, Andrea Falini, Roland G. Henry, Letterio Salvatore Politi and Ettore Salsano. Quantitative Magnetic Resonance Imaging of the Spinal Cord and Brain in Adrenomyeloneuropathy: In Vivo Assessment of Structural Changes. *Brain.* 2016 Jun;139(Pt 6):1735-46.
13. S. Schimrigk, J. Faiss, **W. Köhler**, A. Günther, L. Harms, A. Kraft, S. Ehrlich, C. Fassbender, R. Klingel, J. Galle and F. Hoffmann. Escalation therapy of steroid refractory relapse with tryptophane immunoabsorption – Observational multicenter study with 147 patients. *Eur Neurol.* 2016;75(5-6):300-6.
14. Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O, Kümpfel T, Krumbholz M, Trebst C, Paul F, Pache F, Obermann M, Zeltner L, Schwab M, Berthele A, Jarius S, Kleiter I; **Neuromyelitis Optica Study Group**. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. *J Neurol.* 2016 Mar;263(3):575-82.
15. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; **Neuromyelitis Optica Study Group**. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. *Ann Neurol.* 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554.
16. Rommer PS, Kamin F, Abu-Mugheisib M, **Koehler W**, Hoffmann F, Winkelmann A, Benecke R, Zettl UK. Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients. *CNS Neurosci Ther.* 2016 Jan;22(1):74-9. doi: 10.1111/cns.12474.
17. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston AS, on behalf of the **CARE-MS II Investigators**. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. *Neurology.* 2016 Nov 8; 87(19): 1985–1992.
18. Jany PL, Agosta GE, Benko WS, Eickhoff JC, Keller SR, **Köhler W**, Koeller D, Mar S, Naidu S, Marie Ness J, Pareyson D, Renaud DL, Salsano E, Schiffmann R, Simon J, Vanderver A, Eichler F, van der Knaap MS, Messing A. CSF and Blood Levels of GFAP in Alexander Disease. *eNeuro.* 2015 Oct 1;2(5). pii: ENEURO.0080-15.2015. doi: 10.1523/ENEURO.0080-15.2015.
19. Kunkel A, Fischer M, Faiss J, Dähne D, **Köhler W**, Faiss JH. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. *Front Neurol.* 2015 May 11;6:97. doi: 10.3389/fneur.2015.00097.

20. **Köhler W**, Ehrlich S, Dohmen C, Haubitz M, Hoffmann F, Schmidt S, Klingel R, Kraft A, Neumann-Haefelin T, Topka H, Stich O, Baumgartner A, Fassbender C. Tryptophan immunoadsorption for the treatment of autoimmune encephalitis. *Eur J Neurol*. 2015 Jan;22(1):203-6. doi: 10.1111/ene.12389. Epub 2014 Mar 3.
21. Hoffmann F, Kraft A, Heigl F, Mauch E, Koehler J, Harms L, Kümpfel T, **Köhler W**, Klingel R, Fassbender C, Schimrigk S. Tryptophan-Immunsorption bei Multipler Sklerose und Neuromyelitis optica. *Nervenarzt*. 2015 Feb;86(2):179-86. doi: 10.1007/s00115-014-4239-8.
22. Kamin F, Rommer PS, Abu-Mugheisib M, **Koehler W**, Hoffmann F, Winkelmann A, Benecke R, Zett UK. Effects of intrathecal triamcinolone-acetonide treatment in MS patients with therapy-resistant spasticity. *Spinal Cord*. 2015 Feb;53(2):109-13.
23. Pouwels PJ, Vanderver A, Bernard G, Wolf NI, Dreha-Kulczewski SF, Deoni SC, Bertini E, Kolschütter A, Richardson W, French-Constant C, **Köhler W**, Rowitch D, Barkovich AJ Hypomyelinating leukodystrophies: Translational research progress and prospects. *Ann Neurol*. 2014 Jun 11. doi: 10.1002/ana.24194
24. Rommer PS, Kamin F, Abu-Mugheisib M, Tumani H, Petzold A, **Koehler W**, Hoffmann F, Winkelmann A, Benecke R, Zett UK. Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. *CNS drugs. Mol Diagn Ther* 2014.
25. Hamilton EM, Polder E, Vanderver A, Naidu S, Schiffmann R, Fisher K, Raguz AB, Blumkin L, **H-ABC Research Group**, van Berkel CGM, Waisfisz Q, Abbink TEM, Wolf NI, van der Knaap MS. Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC): further delineation of the phenotype and genotype-phenotype correlation. *Brain*. 2014 Jul;137(Pt 7):1921-30. doi: 10.1093/brain/awu110. Epub 2014 Apr 30
26. Faiss J H, Dähne D, Apel-Neu A, Baum K, Deppe R, Hoffmann F, **Köhler W**, Kunkel A, Matzke M, Sailer M, Zettl U K. Reduced magnetization transfer ratio in cognitively impaired patients at the very early stage of multiple sclerosis: a prospective, multicenter, cross-sectional study. *BMJ Open*. 2014 Apr 10;4(4):e004409. doi: 10.1136/bmjopen-2013-004409
27. Ward-Abel N, **Köhler W**, Matthews V, Uccelli MM, Mouzawak C, Ross AP, Pyciaková L, Winslow A, Kraus J. Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper. *Mult Scler*. 2013
28. Fischer M, A Kunkel, P Bublak, JH Faiss, F Hoffmann, M Sailer, M Schwab, UK Zettl and **W Köhler**. How reliable is the classification of cognitive impairment across different criteria in early and late stages of multiple sclerosis? *J Neurol Sci*. 2014 May 27. pii: S0022-510X(14)00332-3. doi: 10.1016/j.jns.2014.05.042.
29. Christiane Kehler, Samuel Groeschel, Birgit Kustermann-Kuhn, Friederike Bürger, **Wolfgang Köhler**, Alfried Kohlschütter, Annette Bley, Robert Steinfeld, Volkmar Gieselmann and Ingeborg Krägeloh-Mann. Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort. *Orphanet Journal of Rare Diseases*, 2014 Feb 5;9(1):18. doi: 10.1186/1750-1172-9-18

30. **Köhler W**, Ehrlich S, Dohmen C, Haubitz M, Hoffmann F, Jahner K, Klingel R, Kraft A, Neumann-Haefelin T, Topka H, Stich O, Baumgartner A & Fassbender C. Tryptophan immunoadsorption for the treatment of autoimmune encephalitis. *Eur J Neurol*. 2014 Mar 3. doi: 10.1111/ene.12389
31. Franziska Weber, Christoph Wiesinger, Sonja Forss-Petter, Günther Regelsberger, Angelika Einwich, Willi Weber, **Wolfgang Köhler**, Hannes Stockinger, Johannes Berger. X-linked adrenoleukodystrophy: Very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes. *Hum Mol Genet*. 2014 Jan 7, doi:10.1093/hmg/ddt645.
32. Bots ML, Ford I, Lloyd SM, Laurent S, Touboul PJ, Hennerici MG; Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack Vascular Ultrasound Study Investigators. Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin: a randomized controlled trial. *Stroke*. 2014 Aug;45(8):2348-53. doi: 10.1161/STROKEAHA.114.004775. Epub 2014 Jun 24
33. Böttcher T, Rolfs A, Tanislav C, Bitsch A, **Köhler W**, Duning T. Fabry Disease – underestimated in differential diagnosis of Multiple Sclerosis. *PLoS One*. 2013 Aug 28;8(8):e71894. doi: 10.1371
34. Ehrlich S, Fassbender CM, Blaes C, Finke C, Günther A, Harms L, Hoffmann F, Jahner K, Klingel R, Kraft A, Lempert T, Tesch M, Thomsen , Topka H, Jochim J, Veauthier C, **Köhler W**. Therapeutische Apherese bei autoimmuner Enzephalitis. *Der Nervenarzt*, April 2013, Volume 84, Issue 4, pp 498-507
35. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; **CARE-MS II Investigators** . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet* 2012;24;380(9856):1829-39
36. **Köhler, W**, Deppe, R, Faiss, J, Faiss, J.H, Hoffmann, F, Klauer, T, Kunkel, A, Lippert, J, Martin, E.-M, Möller, H, Schilling, H, Sühnel, A, Tiffert, C, Voigt, K, Zettl, U. K. Psychoedukatives Trainingsprogramm für Patienten mit Multipler Sklerose (PTMS): Entwicklung und Evaluation. *Nervenarzt* 2012
37. **Köhler W**, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis *J Clin Apher*. 2011 Dec;26(6):347-55.
38. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; **PERFORM Study Investigators**. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. *Lancet*. 2011 Jun 11;377(9782):2013-22.
39. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; **TRANSFORMS Study Group**. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurol*. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.

40. Trebst C, Berthele A, Jarius S, Kümpfel T, Schippling S, Wildemann B, Wilke C, **NEMOS Study Group**. Diagnostik und Therapie der Neuromyelitis optica. *Der Nervenarzt* 2011, Volume 82, Issue 6, pp 768-777
41. Sieb JP, **Köhler W**. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. *Clin Neurol Neurosurg*. 2010 Nov;112(9):781-4. doi: 10.1016/j.clineuro.2010.06.018. Epub 2010 Jul 21.
42. van der Knaap MS, Lai V, **Köhler W**, Salih MA, Fonseca MJ, Benke TA, Wilson C, Jayakar P, Aine MR, Dom L, Lynch B, Kálmánchey R, Pietsch P, Errami A, Scheper GC. Megalencephalic leukoencephalopathy with cysts without MLC1 defect. *Ann Neurol*. 2010 Jun;67(6):834-7. doi: 10.1002/ana.21980.
43. Weber T, **Köhler W**. Entmarkungserkrankungen. *Der Nervenarzt* 2010, Volume 81, Issue 4, pp 471-496
44. **Köhler W**. Leukodystrophies with late disease onset: an update. *Curr Opin Neurol*. 2010 Jun;23(3):234-41. doi: 10.1097/WCO.0b013e328338313a. Review.
45. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatir BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; **TRANSFORMS Study Group**. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
46. Henze R, W. C. Janzen, F. Schumm, A. Melms, J. P. Sieb, **W. Köhler**, F. Heidenreich, B. Tackenberg für den Ärztlichen Beirat der Deutschen Myasthenie-Gesellschaft (DMG) C. Weber-Schöndorfer^a Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom. Teil 1: Medikamentöse Immunsuppression Immunotherapy for Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome Part 1: Drug-Induced Immunosuppression. *Akt Neurol* 2010; 37(10): 505-517, DOI: 10.1055/s-0030-1265986
47. Henze R, W. C. Janzen, F. Schumm, A. Melms, J. P. Sieb, **W. Köhler**, F. Heidenreich, B. Tackenberg für den Ärztlichen Beirat der Deutschen Myasthenie-Gesellschaft (DMG) C. Weber-Schöndorfer^a Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom. Teil 2: Intravenöse Immunglobuline und Plasmaaustauschverfahren Immunotherapy for Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome Part 2: Intravenous Immunoglobulins and Apheresis Techniques. *Akt Neurol* 2010; 37(10): 518-523, DOI: 10.1055/s-0030-1265985
48. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; **PERFORM Study Investigators**. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. *Cerebrovasc Dis*. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16
49. Semmler A, Bao X, Cao G, **Köhler W**, Weller M, Aubourg P, Linnebank M. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. *J Neurol*. 2009 Aug;256(8):1277-80. doi: 10.1007/s00415-009-5114-6. Epub 2009 Apr 8
50. **Köhler W**. Diagnostic algorithm for the differentiation of leukodystrophies in early MS. *J Neurol*. 2008 Dec;255 Suppl 6:123-6. doi: 10.1007/s00415-008-6023-9.

51. **Multiple Sclerosis Therapy Consensus Group (MSTCG)**, Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. *J Neurol.* 2008 Oct;255(10):1449-63. doi: 10.1007/s00415-008-0061-1. Epub 2008 Oct 29.
52. Maier EM, Mayerhofer PU, Asheuer M, **Köhler W**, Rothe M, Muntau AC, Roscher AA, Holzinger A, Aubourg P, Berger J. X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. *Biochem Biophys Res Commun.* 2008 Dec 5;377(1):176-80. doi: 10.1016/j.bbrc.2008.09.092. Epub 2008 Oct 1
53. Semmler A, **Köhler W**, Jung HH, Weller M, Linnebank M. Therapy of X-linked adrenoleukodystrophy. *Expert Rev Neurother.* 2008 Sep;8(9):1367-79. doi: 10.1586/14737175.8.9.1367. Review.
54. Hehr U, Bauer P, Winner B, Schule R, Olmez A, **Koehler W**, Uyanik G, Engel A, Lenz D, Seibel A, Hehr A, Ploetz S, Gamez J, Rolfs A, Weis J, Ringer TM, Bonin M, Schuierer G, Marienhagen J, Bogdahn U, Weber BH, Topaloglu H, Schols L, Riess O, Winkler J. Long-term course and mutational spectrum of spatacsin-linked spastic paraplegia. *Ann Neurol.* 2007 Dec;62(6):656-65
55. van der Knaap MS, Linnankivi T, Paetau A, Feigenbaum A, Wakusawa K, Haginoya K, **Köhler W**, Henneke M, Dinopoulos A, Grattan-Smith P, Brockmann K, Schiffmann R, Blaser S. Hypomyelination with atrophy of the basal ganglia and cerebellum: follow-up and pathology. *Neurology.* 2007 Jul 10;69(2):166-71.
56. **Köhler W**. Psychosocial aspects in patients with myasthenia gravis. *J Neurol.* 2007 May;254 Suppl 2:II90-2. Erratum in: *J Neurol.* 2008 Feb;255(2):309-10.
57. Linnebank M, Semmler A, Kleijer WJ, van der Sterre ML, Gärtner J, Fließbach K, Sokolowski P, **Köhler W**, Schlegel U, Klockgether T, Wanders RJ, Schmidt S, Wüllner U, Kemp S. The cystathionine beta-synthase variant c.844_845ins68 protects against CNS demyelination in X-linked adrenoleukodystrophy. *Hum Mutat.* 2006 Oct;27(10):1063-4.
58. Linnebank M, Kemp S, Wanders RJ, Kleijer WJ, van der Sterre ML, Gärtner J, Fließbach K, Semmler A, Sokolowski P, **Köhler W**, Schlegel U, Schmidt S, Klockgether T, Wüllner U. Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy. *Neurology.* 2006 Feb 14;66(3):442-3.
59. Wichers-Rother M, Grigull A, Sokolowski P, Stoffel-Wagner B, **Köhler W**. Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone. *J Neurol.* 2005 Dec;252(12):1525-9.
60. Moser HW, Raymond GV, **Koehler W**, Sokolowski P, Hanefeld F, Korenke GC, Green A, Loes DJ, Hunneman DH, Jones RO, Lu SE, Uziel G, Giros ML, Roels F. Evaluation of the preventive effect of glyceryl trioleate-trierycinate ("Lorenzo's oil") therapy in X-linked adrenoleukodystrophy: results of two concurrent trials. *Adv Exp Med Biol.* 2003;544:369-87.
61. Blattner R, Von Moers A, Leegwater PA, Hanefeld FA, Van Der Knaap MS, **Köhler W**. Clinical and genetic heterogeneity in megalencephalic leukoencephalopathy with subcortical cysts (MLC). *Neuropediatrics.* 2003 Aug;34(4):215-8. Review.

62. Schmidt S, Marrosu GM, Kölsch H, Haase CG, Ferenczik S, Sokolowski P, **Köhler W**, Schmidt M, Papassotiropoulos A, Heun R, Grosse-Wilde H, Klockgether T. Genetic variations and humoral immune responses to myelin oligodendroglia glycoprotein in adult phenotypes of X-linked adrenoleukodystrophy. *J Neuroimmunol.* 2003 Feb;135(1-2):148-53
63. Schmidt S, Haase CG, Bezman L, Moser H, Schmidt M, **Köhler W**, Lington C, Klockgether T. Serum autoantibody responses to myelin oligodendrocyte glycoprotein and myelin basic protein in X-linked adrenoleukodystrophy and multiple sclerosis. *J Neuroimmunol.* 2001 Sep 3;119(1):88-94.
64. Alger S, Green A, **Köhler W**, Sokolowski P, Moser H. Proceedings of the 4th International Workshop of the Adrenoleukodystrophy International Research Group (ALD-IRG), University of York, 3 September 1998. *J Inher Metab Dis.* 2000 Jul;23(5):449-52.
65. König A, Happel R, Tchitcherina E, Schaefer JR, Sokolowski P, **Köhler W**, Hoffmann R. An X-linked gene involved in androgenetic alopecia: a lesson to be learned from adrenoleukodystrophy. *Dermatology.* 2000;200(3):213-8.
66. Kloehn S, Arendt T, **Köhler W**, Fölsch UR, Mönig H. Primary adrenal cortex insufficiency and subclinical neurological changes in a young man. Primary adrenal cortex insufficiency (Addison disease) in x-chromosome linked adrenoleukodystrophy. *Internist (Berl).* 2000 Feb;41(2 Pt 2):218-22.
67. Wichers M, **Köhler W**, Brennemann W, Boese V, Sokolowski P, Bidlingmaier F, Ludwig M. X-linked adrenomyeloneuropathy associated with 14 novel ALD-gene mutations: no correlation between type of mutation and age of onset. *Hum Genet.* 1999 Jul-Aug;105(1-2):116-9.
68. Heim P, Claussen M, Hoffmann B, Conzelmann E, Gärtner J, Harzer K, Hunneman DH, **Köhler W**, Kurlmann G, Kohlschütter A. Leukodystrophy incidence in Germany. *Am J Med Genet.* 1997 Sep 5;71(4):475-8.
69. Brennemann W, **Köhler W**, Zierz S, Klingmüller D. Testicular dysfunction in adrenomyeloneuropathy. *Eur J Endocrinol.* 1997 Jul;137(1):34-9.
70. Edwin D, Speedie LJ, **Köhler W**, Naidu S, Kruse B, Moser HW. Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. *Ann Neurol.* 1996 Oct;40(4):675-8
71. Brennemann W, **Köhler W**, Zierz S, Klingmüller D. Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy. *Neurology.* 1996 Aug;47(2):605.
72. Kumar AJ, **Köhler W**, Kruse B, Naidu S, Bergin A, Edwin D, Moser HW. MR findings in adult-onset adrenoleukodystrophy. *AJNR Am J Neuroradiol.* 1995 Jun-Jul;16(6):1227-37

Handbooks and Chapters

1. Moser HW, **Köhler W**, Borel J, Bergin A, Panoscha R, Davoli CT, McGuinness M, Smith K. The Many Faces of X-Linked Adrenoleukodystrophy: Implications for Pathogenesis and the Evaluation of Therapy in Wanders RJA, Schutgens RBH. „Peroxisomal Disorders in Relation to Function and Biogenesis of Peroxisomes“ Elsevier Scientific Publishers, Amsterdam (1995)
2. **Köhler W**, Lange R, Engelsing M, Jacobs J, Hertel G. (1993) 7S-Immunglobulintherapie bei X-

- chromosomaler Adrenoleukodystrophie (X-ALD). In: Internationales Behring Immunologie Symposium „Infektionen und Autoimmunerkrankungen II: Therapie mit Immunglobulinen und deren Derivaten“ Universitätsverlag Jena, 56-71
3. **Köhler W**, Sokolowski P. Clinical Phenotypes, Diagnosis and Treatment of Adulthood X-linked Adrenoleukodystrophy in Berger J, Stöckler-Ipsiroglu S, Köhler W (Hrsg.) Understanding and Treating Adrenoleukodystrophy – present state and future perspectives. (2003) sps publications, Heilbronn
 4. Zettl UK, **Köhler W**, Buchmann J. Multiple Sklerose im Kindes- und Jugendalter. Thieme Verlag 2007, Stuttgart
 5. **Köhler W**, Schwarze J. Enzephalopathien und leukodystrophische Erkrankungen in Klingelhöfer J, Berthele A (Hrsg). Klinikleitfaden Neurologie. 6. Auflage (2017) Urban und Fischer Verlag.
 6. **Köhler W**. Leukodystrophien des Erwachsenenalters in Berlit P. (Hrsg) Klinische Neurologie. 4. Auflage (2017). Springer Verlag.
 7. **Köhler W**, Sieb JP. Myasthenia gravis. 5. Auflage (2012) Uni-Med Verlag, Bremen.
 8. **Köhler W**. Kapitel: Klinik der Multiplen Sklerose; Differentialdiagnose der MS; Pathophysiologisch ansetzende Therapie; Therapie des akuten Schubs; Plasmapherese und Immunadsorption in Schmidt RM, Hoffmann F, Faiss J, **Köhler W**, Zettl U (Hrsg) Multiple Sklerose. 7. Auflage (2017), Urban und Fischer, München und Jena.
 9. Berrouschot J, **Köhler W**, Sakowitz OW. Neurologische Intensivmedizin -kompakt-. Bände 1-7 (Band 7, 2016), Eigenverlag.
 10. **Köhler W**. Kapitel Neuromuskuläre Übertragungsstörungen und Entzündliche Myopathien in Stangel M (Hrsg) Immunglobuline in der Neurologie. UNI-MED Verlag, 4. Auflage 2014.
 11. **Köhler W**. Kapitel Leukodystrophien in Zettl U, Sieb J (Hrsg) Diagnostik und Therapie neurologischer Erkrankungen. Elsevier, 1. Auflage 2018 (in press).